ProfileGDS5678 / 1451648_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 89% 87% 91% 82% 90% 87% 84% 87% 87% 86% 85% 85% 86% 86% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 16.9115889
GSM967853U87-EV human glioblastoma xenograft - Control 26.7410787
GSM967854U87-EV human glioblastoma xenograft - Control 37.4144991
GSM967855U87-EV human glioblastoma xenograft - Control 46.0661282
GSM967856U87-EV human glioblastoma xenograft - Control 57.3477190
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 16.4687487
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 26.0752884
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.6963787
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.6257187
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.6142486
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.3543385
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.4992685
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5897686
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.5196586